SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for NATURES SUNSHINE PRODUCTS INC (NATR) (CIK 0000275053) (NATR) — Jul 16, 2021

NATURES SUNSHINE PRODUCTS INC (NATR) (CIK 0000275053)
Date: July 16, 2021 · CIK: 0000275053 · Accession: 0000000000-21-008796

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-257823

Date
July 16, 2021
Author
Terrence Moorehead
Form
UPLOAD
Company
NATURES SUNSHINE PRODUCTS INC (NATR) (CIK 0000275053)

Letter

United States securities and exchange commission logo July 16, 2021 Terrence Moorehead Chief Executive Officer Nature's Sunshine Products, Inc. 2901 West Bluegrass Blvd., Suite 100 Lehi, Utah 84043 Re:Nature's Sunshine Products, Inc. Registration Statement on Form S-3 Filed July 12, 2021 File No. 333-257823 Dear Mr. Moorehead: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jane Park at 202-551-7439 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: David Marx, Esq.

Show Raw Text
United States securities and exchange commission logo
July 16, 2021
Terrence Moorehead
Chief Executive Officer
Nature's Sunshine Products, Inc.
2901 West Bluegrass Blvd., Suite 100
Lehi, Utah 84043
Re:Nature's Sunshine Products, Inc.
Registration Statement on Form S-3
Filed July 12, 2021
File No. 333-257823
Dear Mr. Moorehead:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Jane Park at 202-551-7439 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       David Marx, Esq.